Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study

By WebmasterJuly 20, 2021November 1st, 2024No Comments

Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study

Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort

See more here

Previous PostRelmada Therapeutics Announces Top- Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
Next PostRelmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostRelmada Therapeutics Announces Top- Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

Next PostRelmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC